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Abstract: Seneca Valley virus (SVV) is a picornavirus with potency in selectively infecting and
lysing cancerous cells. The cellular receptor for SVV mediating the selective tropism for tumors is
anthrax toxin receptor 1 (ANTXR1), a type I transmembrane protein expressed in tumors. Similar to
other mammalian receptors, ANTXR1 has been shown to harbor N-linked glycosylation sites in its
extracellular vWA domain. However, the exact role of ANTXR1 glycosylation on SVV attachment and
cellular entry was unknown. Here we show that N-linked glycosylation in the ANTXR1 vWA domain
is necessary for SVV attachment and entry. In our study, tandem mass spectrometry analysis of
recombinant ANTXR1-Fc revealed the presence of complex glycans at N166, N184 in the vWA domain,
and N81 in the Fc domain. Symmetry-expanded cryo-EM reconstruction of SVV-ANTXR1-Fc further
validated the presence of N166 and N184 in the vWA domain. Cell blocking, co-immunoprecipitation,
and plaque formation assays confirmed that deglycosylation of ANTXR1 prevents SVV attachment
and subsequent entry. Overall, our results identified N-glycosylation in ANTXR1 as a necessary post-
translational modification for establishing stable interactions with SVV. We anticipate our findings
will aid in selecting patients for future cancer therapeutics, where screening for both ANTXR1 and its
glycosylation could lead to an improved outcome from SVV therapy.
Keywords: virus receptor interaction; receptor glycosylation; picornavirus; icosahedral capsid;
cryo-electron microscopy
1. Introduction
Seneca Valley virus (SVV) is a small, non-enveloped RNA virus belonging to the genus
Senecavirus in the family Picornaviridae [1]. The 7280 nucleotide (nt) long positive-sense
single-stranded RNA genome of SVV comprises a 5′ untranslated region (UTR, 666 nt) and
an open reading frame (ORF, 6543 nt) followed by a shorter 3′ UTR of 71 nt and a poly
adenosine (poly(A)) tail of unknown length. The SVV ORF encodes a single 2181 amino
acid long polyprotein, which is later cleaved into a characteristic picornaviral protein
layout, L-4-3-4 [1]. In this layout, L stands for the leader protein and 4-3-4 represents
the four structural proteins VP4, VP2, VP3, and VP1 and seven non-structural proteins
2A–2C and 3A–3D. In the SVV life cycle, two forms of particles exist: mature capsid with
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a packaged genome, and native empty capsid without RNA [2]. In both capsids, VP1 is
arranged around the 5-fold axis, while VP2 and VP3 alternate around the 3-fold axis. VP4
is located in the capsid interior, forming contacts with the RNA near the 5-fold axis [2,3].
Since its serendipitous discovery, phylogenetic analyses of SVV over a span of two
decades have shed light on the existence of three distinct clades [4]. SVV-001 is grouped
as the lone member in clade I without any reported association to human or animal
pathogenicity. SVV-001 selectively infects and replicates in tumor cells of neuro-endocrine
origin and has shown promise in cancer therapeutics [5]. SVV-001 has been tested as a
therapeutic agent in pre-clinical studies and in Phase I/II clinical trials for treating pediatric
solid tumors and small-cell lung cancer [6–10]. In contrast, strains in clades II and III
are linked to idiopathic vesicular disease (IVD) and epidemic transient neonatal losses
(ETNL) in swine [11–17]. Indistinguishable characteristics between SVV-associated IVD
and historical swine diseases raise caution against the possible event of a major outbreak
in the agricultural industry. Thus, in-depth knowledge of the virus biology—in particular
virus structure and host cell-receptor interactions—could provide beneficial information in
further exploiting this virus as a cancer therapeutic or as a virus-like particle (VLP) vaccine.
To date, more than 20 cellular receptors have been identified and characterized among
the members of the Picornaviridae family. Picornavirus receptors mainly fall into the
immunoglobulin superfamily (IgSF), the structure of which consists of a single trans-
membrane domain and tandem repeats of two to five Ig-like domains that form contacts
with the canyon in the viral capsid [18–20]. In addition, non-IgSF receptors, heparan
sulfate [21,22], sialic acid [23], and complement control proteins act as receptors for some
picornaviruses [24,25]. The high-affinity cellular receptor responsible for SVV attachment
is anthrax toxin receptor 1 (ANTXR1) [26], a type I transmembrane protein with three
domains: an extracellular N-terminal von Willebrand factor A (vWA) domain, a trans-
membrane domain, and a C-terminal cytoplasmic domain [27]. ANTXR1, also known as
tumor endothelial marker 8 (TEM8), is expressed in approximately 60% of tumors but
not in non-malignant cells [26]. Its homologous receptor, ANTXR2, is expressed on both
healthy and tumor cells and acts as the main cellular receptor for the protective antigen of
anthrax toxin secreted by the gram-positive bacterium Bacillus anthracis [28]. The cryo-EM
structure of SVV-ANTXR1 showed that despite a large degree of structural and sequence
conservation between the two receptors, the sequence along the SVV binding footprint
shows divergence, thereby limiting SVV attachment only to ANTXR1 [29].
Picornavirus receptors have commonly been found to undergo post-translational mod-
ifications, specifically glycosylation [18]. This glycosylation can be grouped broadly into re-
ceptors with either N-linked glycosylation, O-linked glycosylation, or both N- and O-linked
glycosylation [30]. N-glycosylation is the most prevalent type, accounting for an average
of 0.94 glycosylation sites per 100 aa in mammalian receptors [31]. N-glycosylation has
been well-documented for poliovirus receptor CD155 [32], coxsackievirus-A-virus (CVA)
receptors ICAM-1 [33] and KREMEN-1 [34], coxsackie-B-virus (CVB) receptor CAR [35],
enterovirus 71 (EV71) receptor SCARB [36], and foot-and-mouth disease virus (FMDV)
receptor αVβ6 [37]. Glycan moieties were speculated to be involved in integrin receptor
interactions with FMDV surface-exposed loops [37], whereas sialylation of SCARB en-
hanced the interactions with EV71 [36]. On the contrary, CD155 N-glycosylation in the
D1 domain was shown to decrease its binding affinity to poliovirus [38]. Similar to other
picornavirus receptors, the vWA domain in ANTXR1 harbors multiple glycans, which play
a role in proper folding and trafficking of the receptor to the cell surface [39]. However,
the functional role of ANTXR1 glycosylation with respect to SVV attachment or entry
remains unknown.
In this study, we characterized the glycosylation of recombinant ANTXR1 extracellular
domain fused to a fragment-crystallizable (Fc) region and its importance in SVV-ANTXR1
interactions and cellular infection. Glycopeptide analysis of the recombinant ANTXR1
recognized three N-linked glycosylation sites in total: two localized to the ANTXR1 extra-
cellular domain and one located in the Fc region. Local cryo-EM map refinement of the
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SVV-ANTXR1 asymmetric unit further confirmed the presence of N-glycosylated sites at
N166 and N184 in the ANTXR1 vWA domain. A combination of co-immunoprecipitation
assays and cellular infection experiments showed the necessity of ANTXR1 glycosylation
for successful SVV attachment and cellular entry. The findings from this study could
provide valuable insights into selecting cancer patients for SVV treatments or in designing
inhibitors that can specifically block N-linked glycans in ANTXR1 to prevent SVV infection
in swine.
2. Materials and Methods
2.1. SVV Purification
SVV purification was carried out according to previously published protocols [2].
Briefly, 8 T175 cm2 flasks of H446 wild-type (wt) cells (ATCC, HTB-171) were grown
in Roswell Park Memorial Institute (RPMI) 1640 medium (Catalog no. 1851354, Gibco,
Waltham, MA, USA) and 10% fetal bovine serum (FBS). At ~80% confluency, the medium
was replaced with RPMI-1640 plus 2% FBS, and cells were infected with plaque-purified
SVV at a multiplication of infection of 1, followed by incubation at 37 ◦C for 48 h. Once
the cytopathic effect (CPE) was confirmed after 48 h, cells were subjected to 3 repeated
cycles of freeze-thawing to lyse the cells and release the virus. Lysed cells and medium
were subjected to high-speed centrifugation at 10,000× g for 30 min at 22 ◦C to pellet down
the cells. The resulting supernatant was centrifuged at 120,000× g for 1 h at 4 ◦C using
a Beckman Coulter SW32Ti rotor. The virus pellet was resuspended in CsCl purification
buffer (137 mM NaCl, 5 mM KCl, 25 mM Tris base, 0.8 mM NaH2PO4) at 4 ◦C, overnight.
Resuspended virus was loaded onto a 1.33 g/mL CsCl isopycnic gradient and centrifuged
at 61,580× g for 18 h at 22 ◦C. The band corresponding to SVV full capsids was collected
using an 18-gauge needle and dialyzed overnight in PBS at 4 ◦C.
2.2. SVV-ANTXR1 Interaction
The concentration of purified SVV capsids was measured by using a QubitTM protein
assay kit according to the manufacturer’s instructions [40]. The interaction between SVV
and ANTXR1-Fc was carried out according to methods adapted from previously published
protocols [29]. Purified SVV stock (0.2 mg/mL) and recombinant human ANTXR1-Fc
(1 mg/mL) (NP_115584.1; Met1-Ser321, Catalog no. 13367-H02H, Sino Biological, Beijing,
China) were mixed in equal volumes and incubated at 37 ◦C for 1.5 h, followed by in-
cubation at 4 ◦C for 1.5 h. Recombinant ANTXR1-Fc was expressed and purified from
HEK293 cells.
2.3. Glycopeptide Analysis of ANTXR1 Glycosylation Sites
Glycopeptide analysis was performed by the University of Georgia Complex Car-
bohydrate Research Center. Recombinant human ANTXR1-Fc was subjected to acetone
precipitation to remove excess Tween 80 in the preparation. Precipitated proteins were then
reduced and alkylated, followed by dialysis in Milli-Q water. Dialyzed sample was dried
and ~120 µg of aliquot was measured and divided into 3 aliquots of 40 µg each. Three
aliquots were digested with trypsin, chymotrypsin, and Glu-C. A portion of each digest
was deglycosylated with PNGase F in 18O Water (H218O). Each digest was then profiled by
LC-nSI-MS/MS (Orbitrap-Fusion with EASY nanospray source and Ultimate 3000). The
LC separation was performed on a nano-C18 column using water/acetonitrile gradient
with formic acid. MS/MS was acquired with 3 different fragmentation methods (collision
induced dissociation (CID), electron transfer dissociation (ETD), and higher-energy col-
lisional dissociation (HCD)) for each peptide/glycopeptide ion during the LC-MS run.
The resulting spectra for each run were analyzed manually by searching for the targeted
glycopeptide ions. The structural assignments were annotated based on the observed ion
mass as well as the MS/MS fragmentation data.
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2.4. Co-Immunoprecipitation Studies
SVV was cultured, purified, and titered as previously described [9,41]. For co-
immunoprecipitation experiments, recombinant ANTXR1-Fc protein (0.25 µg) was in-
cubated with magnetic Protein G Dynabeads (Invitrogen, Carlsbad, CA, USA; 30 mg/mL;
1 µL) for 10 min at room temperature in PBS, pH 7.4. Bead-Fc complexes were then in-
cubated in the presence or absence of PNGase F (500 units; NEB, Ipswich, MA, USA) in
1× Glycobuffer (NEB) for 0–24 h at 37 ◦C. Complexes were subsequently washed and
incubated with SVV-001 (2.0 × 1010 vp) for 2 h at 4 ◦C. Triplicate washes of the complexes
were performed with PBS pH 7.4 supplemented with 0.02% Tween-20 (Sigma, St. Louis,
MO, USA), and the bead-Fc-protein complexes were eluted by boiling for 10 min at 90 ◦C
in RIPA buffer supplemented with NuPAGE sample reducing agent and LDS sample buffer
(Invitrogen, Carlsbad, CA, USA). Western blotting was performed as described previ-
ously [26]. Duplicate protein samples were resolved on a 4–12% Bis-Tris polyacrylamide
gel with MOPS running buffer (Invitrogen, Carlsbad, CA, USA). The gel was then stained
using the Pierce Silver Stain kit and imaged using a E-Gel Imager (Invitrogen, Carlsbad,
CA, USA).
2.5. Cell Blocking Studies
SVV-GFP reporter virus contains a fusion protein of GFP flanked with 2A sequences
and was cultured, purified, and titered as previously described [9,41]. SVV-GFP infectious
titers were determined as described previously by flow cytometry [42]. H446wt cells were
seeded in a 6-well tissue culture treated plate (Corning, Corning, NY, USA) 16–24 h prior to
infection and incubated overnight at 37 ◦C. ANTXR1-Fc protein (5 µg/mL) was incubated
in the presence or absence of PNGase F (2.5 × 103 units) in 1× Glycobuffer for 24 h at 37 ◦C
and subsequently incubated with SVV-GFP (MOI = 5) in PBS for 1 h on ice. Protein-virus
solution was then added to cells for 16 h at 37 ◦C. Cells were then incubated with NucBlue
Live ReadyProbe reagent (Invitrogen, Carlsbad, CA, USA) for 20 min at 37 ◦C. Cell images
were obtained with an EVOS FL Auto fluorescence microscope (Invitrogen, Carlsbad,
CA, USA).
2.6. Plaque Formation Assay
H446wt cells were seeded in a 12-well plate at 70% confluency. Next day, the confluent
monolayers of H446wt cells were infected with serial dilutions of SVV in RPMI1640. After
1 h of incubation at 37 ◦C, virus dilutions were removed from the plates and each well
was immediately overlaid with RPMI1640 supplemented with 2% FBS and 1% agarose
(SeaPlaque; catalog number 50100; Lonza, Basel, Switzerland). The plates were stained
with 5 mg/mL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; catalog
number M2128; Sigma, St. Louis, MO, USA) for plaque visualization after 24 h incubation
at 37 ◦C. For deglycosylation assay, H446wt cells were pre-treated with 100 units of PNGase
F for 1 h at 37 ◦C and the excess liquid was removed prior to infection with SVV.
2.7. Focused Classification/Refinement of SVV-ANTXR1 Asymmetric Unit and Modeling
of Glycans
The protocols related to cryo-EM data used in this study were previously published in
our study describing the SVV-ANTXR1 structure [29]. To better visualize the glycosylation
sites in ANTXR1-Fc bound to SVV we sought to perform a localized reconstruction of
one asymmetric unit. To achieve this, imposed I4 symmetry in the particle stack from
final 3D refinement was relaxed to C1 symmetry using the relion_particle_symmetry_expand
command, thus resulting in a particle stack of 406,920 symmetry related copies. This
particle stack was subjected to 3D classification in Relion-3.1 using a custom mask created
by UCSF Chimera “Volume eraser” tool, to include one asymmetric unit in SVV-ANTXR1-
Fc, masking out the remainder of the complex. A cryo-EM map of SVV-ANTXR1-Fc
low-pass filtered at 30 Å resolution was used as the starting reference. 3D classes from
the latter step were further subjected to masked 3D refinement and post-processing in
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Relion-3.1 using the same 3D mask as before. Spatial resolution of the final reconstruction
was calculated to be 6.6 Å based on Fourier shell correlation cut-off of 0.143 between two
independent half-maps.
To model the glycosylation site on ANTXR1-Fc, our previously published cryo-EM
structure of SVV-ANTXR1 (PDB ID 6XC1) was first manually fitted into the cryo-EM map
using UCSF Chimera [43]. Glycan tree accounting for the additional density in the cryo-EM
map was manually built using the carbohydrate module in Coot [44]. All the figures were
generated in UCSF ChimeraX.
3. Results
3.1. Profiling of Glycosylation Sites in ANTXR1
As a first step toward recognizing potential N-linked glysosylation sites in ANTXR1-Fc
recombinant preparations used in this study, we combined different proteolytic degrada-
tion protocols followed by deglycosylation with PNGase F in the presence of 18O water to
obtain glycopeptides suited for LC-nSI-MS/MS analysis. ANTXR1-Fc from Sino Biologi-
cal was expressed and purified from HEK293 cells and therefore, was subject to similar
glycosylation modifications as endogenous ANTXR1. PNGase F acts as a broad-spectrum
enzyme that cleaves all N-linked hybrid or complex oligosaccharides found in plants
and mammals, except in the presence of a core α1, 3 fucose connected to asparagine-
linked N-acetylglucosamine (NAG) [45,46]. In such instances, the prior denaturation of
protein is essential for an efficient cleavage by PNGase F. Therefore, we treated separate
aliquots of ANTXR1-Fc with trypsin, chymotrypsin, and Glu-C. A combination of different
proteases allowed us to obtain spectra of glycopeptide ions accounting for all potential
N-glycosylation sites. A portion of each digest was deglycosylated with PNGase F in 18O
water to convert the glycan-modified asparagine to an 18O aspartic acid residue, causing a
subtle mass shift of 3 Da [47].
Our 18O labeling experiment recognized three N-linked sites at residues N166 and
N184 in the extracellular vWA domain of ANTXR1 and at N81 in the fused Fc domain
(Table 1). These findings were in agreement with previously discovered N-linked glyco-
sylation sites in both ANTXR1 and ANTXR2 [39]. In our analysis, N166 and N184 were
found to be heavily glycosylated. All N166 sites showed 100% glycan occupancy, while
N184 sites were mostly glycosylated (Table 1). These glycosylated sites in the vWA domain
carried both bi-antennary and tri-antennary sialylated and fucosylated complex glycans.
Notably, some of the glycans in latter N-linked sites contained a LacdiNAc antenna in the
structure. In addition, one sulfated N-glycan was shown to be linked to N184. Overall,
the high degree of LacdiNAc expression, heavy fucosylation, and sulfation observed here
showed similarities to glycoprotein expressed in human cell lines [48].
3.2. Cryo-Electron Microscopy Reconstruction of ANTXR1 Glycosylation Sites
To further visualize and dissect the role of ANTXR1 glycosylation in the context
of interactions with SVV, we reprocessed the data from our previously published SVV-
ANTXR1 cryo-EM structure (Figure 1A). In the original cryo-EM reconstruction, imposing
strict icosahedral symmetry averaging during the reconstruction process attenuated the
signal of asymmetric or structurally heterogeneous features such as glycans due to their
local variability. In order to overcome this issue, we used local symmetry expansion,
followed by an established focused classification and orientation refinement approach to
resolve these local glycan features more clearly. In this method, the particle stack from the
final 3D refinement of SVV-ANTXR1 was symmetry-expanded [49], thus creating a stack
containing symmetry related copies [50]. Then, we applied a soft-edged mask to cover one
asymmetric unit of the reconstruction plus a distance of 12 pixels extended in all directions
(Figure 1A). Initial 3D classification of the data set did not recognize any distinct structural
heterogeneity and had similar features (Figure 1B), which led us to refine the entire data set
to obtain the final cryo-EM map of the SVV-ANTXR1 asymmetric unit at 6.6 Å resolution
(Figure 1C).
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Table 1. Glycan profiles of N166, N184, and N81 (Fc) glycosylation sites as identified by LC-nSI-MS/MS analysis.
Profiled Glycan N166 N184 N81 (Fc)
Deoxyhex1HexNAc5Hex4
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Figure 1. Symmetry-expanded cryo-EM reconstruction of SVV-ANTXR1-Fc asymmetric unit. (A) Cryo-EM reconstruction
(map contoured at 3.66 σ above average) of SVV-ANTXR1-Fc complex at 3.8 Å resolution (EMD-7772). A soft-edged mask
enclosing one asymmetric unit was applied to symmetry-related copies of the particle. (B) All four 3D classes generated
from classification of masked symmetry-expanded particles display features of receptor glycosylation. (C) Electron
potential map (map contoured at 0.34 σ above average) corresponding to one SVV capsid asymmetric in complex with
ANTXR1 vWA domain. Blue, green, red and magenta colored ribbons represent VP1, VP2, VP3, and ANTXR1, respectively.
Masked-out cryo-EM densities for N166 (D) and N184 (E) glycosylation sites are located on the α4 helix and α5-β5 loop of
ANTXR1. Fitted atomic glycan coordinates modeled as the common glycan composition are shown in maroon ball-and-stick
representation. Common glycan composition from N-link to the first branching site of the latter two sites is shown in the
schematic diagrams (D,E right, and red-dashed box in Table 1). Fucose, N-acetylglucosamine and mannose are depicted by
red triangles, blue rectangles, and green spheres, respectively.
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In agreement with our glycopeptide profiling, we observed two glycosylation sites
at N166 and N184 in the extracellular vWA domain of ANTXR1 (Figure 1D,E). We could
observe and fit the coordinates corresponding to a complex glycan profile, starting from the
N-link up to its first bisection, a composition common to all of the glycans detected by LC-
nSI-MS/MS analysis (red-dashed box, Table 1). Features in the cryo-EM electron potential
map corresponding to N166 appeared to be better resolved compared to map detail at the
N184 site as evident from the appearance of glycan branching at a lower threshold (contour
level of 4 σ vs 3.4 σ above average). This suggested a higher degree of order within the
glycans at N166 in comparison to N184, as shown by the MS analysis. In picornavirus
receptors, N-linked glycans are not involved in direct interactions with the capsid, except
in the case of interactions between αVβ6 and FMDV, where N266 linked glycan was shown
to extend to the capsid surface, presumably bridging the integrin to the virus surface [37].
ANTXR1 vWA adopts a similar “Rossman fold” to that of αVβ6 and interacts with the
surface-exposed loops in VP1-VP3, reminiscent of FMDV- αVβ6 interactions. However,
both N-linked glycans in the ANTXR1 vWA domain extend parallel to the capsid floor.
Thus, neither N-linked glycan at N166 nor N184 was in close proximity to SVV surface-
exposed loops, excluding a direct role of these glycans in mediating virus contact.
3.3. ANTXR1 Glycosylation Is Essential for SVV Attachment and Entry
In order to assess if N-glycosylation on ANTXR1 is necessary for successful viral
attachment and entry, we performed infection studies with GFP-tagged virus (SVV-GFP)
and ANTXR1-Fc protein that was pre-incubated in the presence or absence of PNGase F
(Figure 2A). Visualization of SVV-GFP infected H446wt cells by fluorescence microscopy
revealed that when SVV-GFP is pre-incubated with ANTXR1-Fc, all of the receptor binding
sites on the SVV capsid become saturated, ergo blocking viral entry into cells. However, in
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4. Discussion
Glycosylation in viral proteins or their receptors is a highly regulated posttranslational
modification affecting their tertiary structure, function, stability, and downstream cellu-
lar signaling pathways. Viral protein or receptor glycosylation can generally be broadly
categorized into two main groups: N-linked and O-linked. In N-linked glycosylation,
glycans are attached to the asparagine residue in an Asp-X-Ser/Thr sequon, where X
can be any amino acid except for proline. In O-linked glycosylation, the sugar moiety is
attached to the oxygen atom of a serine or threonine residue. Viral protein glycosylation
has been reported for enveloped viruses such as coronavirus spike protein [51], ebola
virus glycoprotein [52], hemagglutinin glycoprotein of influenza virus [53], envelope gly-
coproteins of flaviviruses [54,55], and Lassa virus envelope glycoprotein [56]. Although
multiple roles have been suggested for glycosylation with respect to viral pathogenesis,
immune evasion by heavy glycan shielding or using shed/secreted glycoproteins remains
the primary role [57]. Second to this role, glycans in viral envelope proteins act as attach-
ment factors [57,58]. Alternatively, for non-enveloped viruses such as adenoviruses [59],
rotaviruses [60], reoviruses [61], and picornaviruses [23,62], this mechanism reverses to
utilize cell surface sialic acid/poly-sialic acid or glycans on cellular receptors as attach-
ment factors.
In picornaviruses, the usage of sialic acid as an attachment factor has been reported
for members in the genus Enterovirus such as CVA24v, EV68, EV70, and EV71 [23,62].
Glycosylation sites observed in picornavirus receptors describe a rich geometry (Figure 3).
For instance, N-linked glycans in αVβ6 integrin form additional contacts between the
receptor and surface-exposed loops of FMDV capsid proteins [37]. Interestingly, heavy N-
linked glycosylation in CD155 abrogates poliovirus infectivity [38], a testament to plausible
steric hindrance by surrounding glycans when the receptor needs to reach the capsid
floor to complete its interaction with the capsid, as opposed to forming contacts with
surface-exposed loops. Hence, picornaviruses are a group of viruses in which receptor
glycosylation can be expressed as a “double-edged sword”, rather than an exclusively
beneficial receptor modification favoring viral entry in every case.
To further our knowledge of the functional role of receptor glycosylation in picor-
naviruses, we investigated the glycosylation in the SVV receptor, ANTXR1. In agreement
with previous literature, our 18O labeling experiment in conjunction with LC-MS analysis
revealed two glycosylation sites at N166 and N184 in the extracellular vWA domain of
ANTXR1 and one glycosylation site at N81 located in the fused Fc domain. N-glycosylation
in ANTXR1 has also been shown to be essential for protein folding, stability, trafficking,
and ligand binding [39]. This pattern of N-glycosylation in ANTXR1 is also observed in
ANTXR2, albeit less dependent on its functional roles. The presence of N-glycans in the
vWA domain in ANTXR1 was visible in its complexed state with SVV. Symmetry expanded
reconstruction of the SVV-ANTXR1 asymmetric unit confirmed the presence of two N-
glycosylation sites in the vWA domain, which extended parallel to the SVV capsid surface,
therein demonstrating no contacts with surfaced-exposed loops. Despite the absence of
any interactions between ANTXR1 glycans and SVV capsid, ANTXR1 deglycosylation was
able to abrogate viral entry into the small-cell lung cancer cell line H446wt, highlighting
its stringent effect on receptor function. While the effect of N-glycosylation on the confor-
mational stability of ANTXR1 and ANTXR2 has not been extensively investigated, it has
been shown that N-glycosylation is essential for conformational stability in extended open
conformation of integrins [63]. The same observation presumably holds true for ANTXR1,
ligand binding open conformation, which closely resembles the integrin open state. This
could explain the complete loss of interactions, subsequent viral entry, and infection when
ANTXR1 is deglycosylated by PNGase F.
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cellular receptor αVβ6 integrin (5NEM). Virus receptor complex of SVV and vWFA domain of ANTXR1 (6CX1).
Our results immediately suggest two important therapeutic applications: (1) As a
biomarker for screening for patients with glycosylated receptors in tumors, as we have
shown that glycosylation is essential for SVV binding, entry and subsequent infection. (2)
The specific role of ANTXR1 in swine remains unknown and this eliminates the possibility
of using enzymatic cleavage of ANTXR1 glycans. Nonetheless, as shown with other
viruses such as influenza and HIV, broad spectrum lectins can be directed against heavily
fucosylated and sialylated glycans in ANTXR1 with the overarching goal of triggering a
teric hindrance in the icinity of the SVV binding site.
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